Safety and efficacy of mirikizumab versus secukinumab and placebo in the treatment of moderate-to-severe plaque psoriasis (OASIS-2): a phase 3, multicentre, randomised, double-blind study

https://www.thelancet.com/journals/lanrhe/article/PIIS2665-9913(23)00120-0/fulltext